News Conference News ESC 2017 CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS Todd Neale August 30, 2017
News Conference News ESC 2017 Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed Michael O'Riordan August 29, 2017
News Conference News ESC 2017 VIVA: Could Population-Wide Screening Trial for AAA, PAD, and Hypertension Save Lives at Low Cost? Shelley Wood August 28, 2017
News Conference News ESC 2017 European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts Shelley Wood August 27, 2017
News Conference News ESC 2017 COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease Todd Neale August 27, 2017
News Conference News ESC 2017 CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease Todd Neale August 26, 2017
News Daily News Evolocumab Not Cost-Effective at Current List Price Michael O'Riordan August 23, 2017
News Daily News TAVR in the US: Regional Variations in Numbers, Outcomes Michael O'Riordan August 22, 2017
News Daily News FDA Clearance of Modified Devices Relies Heavily on Weak Studies, Surrogate Endpoints Michael O'Riordan August 16, 2017
News Daily News Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness Michael O'Riordan August 08, 2017
News Daily News How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues Leah Lawrence August 01, 2017
News Daily News Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study Leah Lawrence July 24, 2017
News Conference News SCCT 2017 Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See? Yael L. Maxwell July 10, 2017
News Daily News Tool May Help Select Patients for Endovascular Stroke Treatment Todd Neale May 15, 2017
News Daily News Visits Nixed: Efforts to Limit Pharma Reps’ Influence Seem to Bear Fruit Caitlin E. Cox May 02, 2017
News Daily News Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows Michael O'Riordan March 31, 2017
News Conference News ACC 2017 Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe Todd Neale March 18, 2017
News Daily News NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease Todd Neale March 14, 2017